The Wnt signaling pathway is highly activated in trastuzumab-resistant breast cancer cells, suggesting the inhibition of the Wnt/β-catenin pathway as a promising therapeutic strategy to improve the effectiveness of HER2-targeted treatments [19,20]. This evidence concerns the gene ERBB2 and breast cancer.